We are live on ! Find out more
LENZ

LENZ Therapeutics
LENZ

66 hedge funds and large institutions have $81.2M invested in LENZ Therapeutics in 2023 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 22 increasing their positions, 14 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

57% more repeat investments, than reductions

Existing positions increased: 22 | Existing positions reduced: 14

36% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 11

11% more capital invested

Capital invested by funds: $72.9M → $81.2M (+$8.38M)

6% more funds holding

Funds holding: 62 → 66 (+4)

0.38% more ownership

Funds ownership: 7.31% → 7.68% (+0.38%)

0% more call options, than puts

Call options by funds: $1.53M | Put options by funds: $1.53M

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

Holders
66
Holders Change
+4
Holders Change %
+6.45%
% of All Funds
1.04%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
15
Increased
22
Reduced
14
Closed
11
Calls
$1.53M
Puts
$1.53M
Net Calls
+$3K
Net Calls Change
+$18K

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$3.43M
2
PM
Prosight Management
Texas
+$2.35M
3
State Street
State Street
Massachusetts
+$1M
4
Geode Capital Management
Geode Capital Management
Massachusetts
+$773K
5
CA
CHI Advisors
New York
+$659K

Top Sellers

Rank Fund Capital Flow
1
KPF
K2 Principal Fund
Ontario, Canada
-$2.38M
2
LCM
Laurion Capital Management
New York
-$1.4M
3
Verition Fund Management
Verition Fund Management
Connecticut
-$1.11M
4
WSL
Western Standard LLC
California
-$914K
5
Morgan Stanley
Morgan Stanley
New York
-$378K
Name Holding Trade Value Shares
Change 		Change in
Stake
AC
26
Aldebaran Capital
Indiana
$338K – – –
Dimensional Fund Advisors
27
Dimensional Fund Advisors
Texas
$273K +$152K +7,631 +103%
Charles Schwab
28
Charles Schwab
California
$213K +$183K +9,150 +361%
Bank of New York Mellon
29
Bank of New York Mellon
New York
$195K +$214K +10,718 New
Morgan Stanley
30
Morgan Stanley
New York
$187K -$378K -18,915 -65%
CIC
31
Cornercap Investment Counsel
Georgia
$173K – – –
Bank of America
32
Bank of America
North Carolina
$170K -$30K -1,502 -14%
MAM
33
Marquette Asset Management
Minnesota
$107K – – –
PCM
34
Prelude Capital Management
New York
$105K +$24.1K +1,205 +26%
D.E. Shaw & Co
35
D.E. Shaw & Co
New York
$104K +$27.1K +1,357 +31%
N
36
Nuveen
North Carolina
$103K +$113K +5,677 New
Millennium Management
37
Millennium Management
New York
$94.4K -$105K -5,273 -50%
DC
38
Diametric Capital
Massachusetts
$94.4K +$104K +5,186 New
New York State Common Retirement Fund
39
New York State Common Retirement Fund
New York
$94.4K +$104K +5,186 New
Goldman Sachs
40
Goldman Sachs
New York
$90.2K +$61.3K +3,070 +163%
RhumbLine Advisers
41
RhumbLine Advisers
Massachusetts
$75.6K +$83K +4,156 New
JP Morgan Chase
42
JP Morgan Chase
New York
$62K +$63.9K +3,198 +1,523%
UBS Group
43
UBS Group
Switzerland
$51.9K +$31.3K +1,569 +122%
AC
44
Annandale Capital
Texas
$47K – – –
Wells Fargo
45
Wells Fargo
California
$36K +$29.9K +1,498 +313%
AIG
46
American International Group
New York
$35.1K +$38.5K +1,927 New
LCM
47
Laurion Capital Management
New York
$31.7K -$1.4M -70,128 -98%
EAM
48
Erste Asset Management
Austria
$30.8K – – –
Invesco
49
Invesco
Georgia
$30.6K +$33.5K +1,679 New
Citigroup
50
Citigroup
New York
$24.3K +$24.7K +1,238 +1,303%
1
2
3

LENZ Hedge Fund Activity: Q2 2023 in Review

66 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in LENZ Therapeutics (LENZ) for Q2 2023, worth a combined $81.2M — up 11% from $72.9M a quarter earlier.

Buyers outnumbered sellers: 15 funds opened new LENZ positions and 11 closed out — a net gain of 4 holders — while 22 added to existing stakes and 14 trimmed.

The largest buyer was BlackRock, adding an estimated $3.43M. The largest seller was K2 Principal Fund, exiting entirely with an estimated $2.38M sold.

  • 66 institutional investors held LENZ Therapeutics (LENZ) as of Q2 2023, up from 62 in Q1 2023.
  • Funds reported $81.2M of LENZ Therapeutics stock for Q2 2023, up 11% quarter-over-quarter.
  • 15 funds opened new LENZ Therapeutics positions in Q2 2023 and 11 closed out, a net change of +4 holders.
  • The largest LENZ Therapeutics buyer in Q2 2023 was BlackRock, an estimated $3.43M added.
  • The largest LENZ Therapeutics seller in Q2 2023 was K2 Principal Fund, an estimated $2.38M sold.

Based on aggregated 13F filings for Q2 2023.